STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
The panel vote moves multi-cancer early detection toward an FDA decision that also gates insurance coverage.
TL;DR
- An FDA advisory panel endorsed Grail's Galleri blood test for cancer, saying its benefits outweigh its risks, STAT reported.
- MarketWatch noted the test screens for 50 cancers and that coverage by Medicare and other insurers hinges on FDA approval.
- The vote count and the FDA's decision timeline were not in the collected data, and an advisory vote is not an approval.
An FDA advisory panel endorsed Grail's blood test for cancer, saying its benefits outweigh its risks, STAT reported. [1]
The commercial question comes next. MarketWatch reported that the test screens for 50 cancers and that whether Medicare and other health insurers cover it hinges on FDA approval. [2]
Why it matters
A positive panel vote moves multi-cancer early detection closer to an FDA decision, which in turn gates Medicare and commercial coverage, the reimbursement question that decides whether the category becomes a large screening market. The outcome also matters for Markets.
Editor's note
The vote count and the FDA's decision timeline were not in the collected data; an advisory vote is not an approval. This is not medical advice.